Day: October 27, 2025

A Media Snippet accompanying this announcement is available by clicking on this link. FORT WORTH, Texas, Oct. 27, 2025 (GLOBE NEWSWIRE) — SEGG Media Corporation (NASDAQ: SEGG, LTRYW) (“SEGG Media” or “the Company”), the global sports, entertainment, and gaming group, today announced the official launch of the new Sports.com App, now available for download on the Apple App Store® and other popular app marketplaces. The release marks a major step forward in the Company’s global sports-growth strategy, bringing fans closer to live and on-demand sports content across emerging markets. The new Sports.com App consolidates SEGG Media’s expanding sports portfolio into an easy-to-use platform that offers live streams, highlights, and exclusive interactive features. The app serves as a next-generation social-sports hub designed to drive...

HOUSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) — Sysco Corporation, the official wholesale food distributor for the prestigious MICHELIN Guide in Houston, is honored to collaborate to announce the latest Texas recipients of Michelin’s coveted stars. This partnership will be celebrated at the 2025 MICHELIN Guide Texas Ceremony on October 29 in Houston, which will showcase Sysco’s high-quality, premium products and culinary expertise. The MICHELIN Guide is renowned for its coveted ratings and in-depth reviews of restaurants worldwide, representing the pinnacle of gastronomic achievement. “We are honored to partner with the MICHELIN Guide to honor chefs whose extraordinary culinary achievements bring families together, create lifelong memories and experiences, helping to create new memories and experiences for families around this great...

                                                                                                          Lysaker, 27 October 2025 This is a re-submission of the announcement posted at 14:46, with reference to the correct fund (SKAGEN Focus A) at the bottom of this text. With reference to Nasdaq Copenhagen’s rules for issuers of UCITS units, we hereby notify that incorrect intrinsic values were reported on 24 October for SKAGEN Focus A as detailed below:Symbol Fund name Price date Time  Correct IV Reported IV Deviation (error)SKIFOA SKAGEN Focus A 24.10.2025 P0905          156,70 159,87 2,02 %SKIFOA SKAGEN Focus A 24.10.2025 P1535          156,72 159,89 2,02 %SKIFOA SKAGEN Focus A 24.10.2025 P0935          156,41 159,57 2,02 %SKIFOA SKAGEN Focus A 24.10.2025 P1005          156,42 159,58 2,02 %SKIFOA SKAGEN Focus...

First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, Oct. 27, 2025 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its recent attendance at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The Conference, held October 22-26, 2025, in Boston, MA, was hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NIC), and the European Organisation for Research and Treatment of Cancer (EORTC). MAIA’s Sr. Medical Director, Victor Zaporojan, M.D., presented a Trial in Progress poster titled “A Phase 2 Study of Ateganosine (THIO; 6-thio-2′-deoxyguanosine)...

Validating the predictive power of Glidelogic’s AI-driven policy foresight platform Background LAS VEGAS, Oct. 27, 2025 (GLOBE NEWSWIRE) — via IBN — Glidelogic Corp. (OTCQB:GDLG, “Glidelogic,” or “the Company”) today announced the successful validation of its pre-Plenum forecast following the conclusion of the Fourth Plenary Session of the 20th Central Committee of the Chinese Communist Party (CCP). With the Plenum’s official communiqué now public, Glidelogic’s Policy Intelligence Suite achieved a weighted forecast hit rate of 83.8%, including 10 full matches, 4 partial matches, and 2 early/weak matches in predicting key directions of China’s 15th Five-Year Plan (2026–2030). This performance underscores the accuracy and significance of Glidelogic’s forecast — released...

SHENZHEN, CHINA, Oct. 27, 2025 (GLOBE NEWSWIRE) — China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on  27 October 2025, the Group through its subsidiary CMS VISION INTERNATIONAL MANAGEMENT LIMITED entered into a Distribution Agreement (the “Agreement”) with Novartis Pharma Services AG (“Novartis”) for Ranibizumab Injection (“Lucentis®”) and Brolucizumab Injection (“Beovu®”). In accordance with the Agreement, the Group has obtained the exclusive right to import, distribute, sell and promote as specifically agreed upon in the Agreement in the People’s Republic of China (for the purpose of the Agreement, excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region and Taiwan) ; Novartis will continue to be responsible for the production and supply of the products....

Distinguished Investor Group Includes Kraken, American Ventures, Exodus (NYSE: EXOD), XtalPi (2228.hk), DL Holdings (1709.hk) GPTX by Jihan Wu and Leading Institutions World No. 1 and 4-time Grand Slam champion Aryna Sabalenka expands her stake in Prenetics Adrian Cheng, one of Asia’s most influential visionaries and an original cornerstone investor in Prenetics’ IPO increases his stake, reflecting enduring conviction in the company’s global vision IM8 Achieves $100 Million in Annual Recurring Revenue Within 11 Months of Launch IM8 Guidance $180 to $200 Million Revenue in 2026, Driving Company Toward Multi-Billion Dollar Valuation Prenetics CEO Danny Yeung to Host Investor Conference Call, Today at 11:00am ET CHARLOTTE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) — Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”),...

WUXI, China, Oct. 27, 2025 (GLOBE NEWSWIRE) — LOBO Technologies Ltd. (Nasdaq: LOBO), a developer and manufacturer of electric mobility and smart-hardware products, today announced an updated financial forecast for the fiscal year ending December 31, 2025. According to the latest forecast, the Company expects continued strong growth in both revenue and profitability. Total revenue for fiscal year 2025 is projected to range between $28 million and $30 million, representing about 30-40% increase compared with fiscal 2024 revenue of $21.2 million. The Company anticipates achieving a gross profit margin of approximately 17%, an improvement of almost 5 percentage points over 2024, and expects to report a gross profit of approximately $4.8 million. Based on current projections, LOBO anticipates a turnaround to profitability, with net...

Vancouver, Canada, Oct. 27, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced the appointment of Mary-Elizabeth Gifford as Chief of Global Impact. In this role, Gifford will lead efforts to strengthen Clearmind’s US partnerships, governmental and regulatory advocacy, and strategic alliances in Washington, D.C. and New York, bridging research, regulation, and patient care to accelerate the advancement of innovative psychedelic medicines. Prior to joining Clearmind, Gifford served as Chief of Global Impact at Psyence BioMed, a Nasdaq-listed biopharmaceutical company focused on nature-derived...